Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LO MINASTRIN FE vs LARIN 1.5/30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Inhibits ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, inhibiting sperm penetration; alters endometrial lining, reducing implantation likelihood.
Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females ≥15 years of age who have no known contraindications, desire oral contraception, and have achieved menarche
Prevention of pregnancy
1 tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol/ferrous fumarate 75 mg) orally once daily for 28 consecutive days.
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
Norethindrone: 8-11 hours; ethinyl estradiol: 12-16 hours. Steady-state achieved after 5-7 days of dosing.
Ethinyl estradiol: 13-19 hours; Norethindrone: 7-9 hours. Steady-state achieved in ~5-7 days.
Hepatic via CYP3A4 (ethinyl estradiol) and primarily reduction and conjugation (norethindrone); undergoes first-pass metabolism.
Ethinyl estradiol: primarily CYP3A4; norethindrone: primarily CYP3A4, with some reduction to active metabolites.
Renal: 40-50% as conjugated metabolites; fecal: 20-30% via biliary excretion; unchanged drug <1%.
Renal (40% as metabolites, <10% unchanged); fecal (50% as metabolites); biliary (minor).
Norethindrone: 97% bound (primarily to albumin and SHBG); ethinyl estradiol: 98% bound (primarily to albumin).
Ethinyl estradiol: 97-98% bound to albumin; Norethindrone: 93-99% bound to SHBG and albumin.
Norethindrone: 4 L/kg; ethinyl estradiol: 2-4 L/kg; reflects extensive tissue distribution and binding to sex hormone receptors.
Ethinyl estradiol: 2.5-5 L/kg; Norethindrone: 2-4 L/kg. Indicates extensive tissue distribution.
Oral: norethindrone ~64%, ethinyl estradiol ~40-48% due to first-pass metabolism.
Oral: Ethinyl estradiol ~40-50% (first-pass metabolism); Norethindrone ~50-60% (first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). Contraindicated in severe renal impairment (GFR <30 m L/min) or acute renal failure due to potential for hyperkalemia from ferrous fumarate.
No dose adjustment required in mild to moderate renal impairment (Cr Cl >=30 m L/min). Use contraindicated in severe renal impairment (Cr Cl <30 m L/min) or renal failure due to potential for fluid retention and hyperkalemia.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A, use caution; consider lower dose estrogen combination if necessary.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A, lowest possible effective dose should be used with close monitoring of liver function.
Not indicated for use prepubertal. Approved for females of reproductive potential; safety and efficacy in children <12 years not established. Follow adult dosing postmenarche.
Post-menarche adolescents: same dosing as adults (one tablet daily for 21 days, then 7 days placebo). Safety and efficacy in pre-menarche girls have not been established.
Not indicated for use in postmenopausal women. In women >35 years who smoke, use is contraindicated due to increased cardiovascular risk.
Not indicated for postmenopausal women. No specific geriatric dose adjustments; however, consider increased risk of thromboembolic events and cardiovascular disease in women aged >40 years who smoke or have other risk factors.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (>35 years) and with heavy smoking (≥15 cigarettes/day). Women >35 years who smoke should not use combination oral contraceptives.
Cigarette smoking increases risk of serious cardiovascular events. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebrovascular accidents, myocardial infarction),Hepatic disease (benign/malignant tumors),Hypertension,Gallbladder disease,Carbohydrate/lipid metabolism effects,Ocular changes (retinal thrombosis),Headache/migraine,Uterine bleeding irregularities,Depression,Cervical cancer screening,Pregnancy test prior to initiation,Lactation (possible decreased milk production)
Cardiovascular disease risk: smoking, hypertension, diabetes, hyperlipidemia,Thromboembolic events: increased risk in surgery, postpartum, or immobilization,Liver disease: discontinue if jaundice develops,Gallbladder disease: increased risk,Glucose intolerance: monitor in diabetics,Blood pressure elevation: monitor periodically,Depression: discontinue if severe
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Carcinoma of endometrium or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Heavy smoking (>15 cigarettes/day) in women >35 years
Current or history of venous thromboembolism,Cerebrovascular or coronary artery disease,Uncontrolled hypertension,Diabetes with vascular involvement,Known or suspected pregnancy,Liver tumors or active liver disease,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component,Cigarette smoking in women over 35
No significant food interactions. Grapefruit juice may increase ethinyl estradiol levels, but clinical significance is minimal. Avoid alcohol if liver function is compromised. Iron absorption from ferrous fumarate is enhanced by vitamin C, but not clinically important.
Grapefruit juice may increase ethinyl estradiol levels; avoid excessive consumption. No specific dietary restrictions; can be taken with or without food.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester use associated with cardiovascular defects, neural tube defects; second/third trimester use associated with fetal genital changes, hepatic adenoma.
First trimester: No consistent evidence of major malformations, but a small increased risk of cardiovascular defects and oral clefts cannot be excluded. Second and third trimesters: Associated with adverse fetal outcomes including low birth weight, preterm delivery, and neonatal withdrawal symptoms. Avoid use during pregnancy due to known risks.
Excreted in breast milk in small amounts (M/P ratio ~0.5). No adverse effects reported in infants, but may reduce milk production. Use with caution.
Small amounts of ethinyl estradiol and norethindrone transfer into breast milk, with a milk-to-plasma ratio approximately 0.2-0.3 for norethindrone and <0.1 for ethinyl estradiol. May reduce milk production and composition. Use caution and consider alternative contraception in nursing mothers.
No dose adjustment indicated as drug is contraindicated in pregnancy.
Contraindicated in pregnancy; no dose adjustment is applicable as the drug should be discontinued immediately upon confirmed pregnancy.
LO MINASTRIN FE is a low-dose combination oral contraceptive (1 mg norethindrone acetate / 20 mcg ethinyl estradiol) with ferrous fumarate tablets. It is indicated for contraception and may improve menstrual regularity. The iron component is not bioavailable during active hormone intake; iron tablets are placebo-day supplements. Monitor for thromboembolic risks, especially in smokers over 35. Breakthrough bleeding is common in the first few cycles. Do not use in hepatic disease or known pregnancy.
Larin 1.5/30 is a monophasic combination oral contraceptive containing 1.5 mg norethindrone acetate and 30 mcg ethinyl estradiol. It is indicated for prevention of pregnancy and may also be used for management of acne and menstrual disorders. Advise patients to take at the same time daily to maintain consistent hormone levels. Counsel about breakthrough bleeding, especially during first cycles. Monitor for thrombotic events; use with caution in women with migraine with aura, hypertension, or smoking history over age 35. Effectiveness may be reduced with strong CYP3A4 inducers. Consider alternative contraception if patient is on chronic enzyme-inducing drugs. Use of NSAIDs can increase risk of breakthrough bleeding. Not recommended during breastfeeding or pregnancy.
Take one tablet daily at the same time; the last 7 tablets contain iron instead of hormones.,Missed dose: if missed within 12 hours, take it as soon as remembered; if more than 12 hours, skip the missed dose and continue schedule; use back-up contraception for 7 days.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35 years old.,Inform your healthcare provider of any new onset headaches, chest pain, leg pain/swelling, or visual disturbances.,Breakthrough bleeding is common initially; if persistent, consult your doctor.,Use additional non-hormonal contraception during first 7 days of starting the pill.,Store at room temperature; keep out of reach of children; iron tablets may be harmful to children if ingested.
Take one tablet at the same time each day, with or without food.,If you miss a dose, follow the instructions in the package insert; use backup contraception if needed.,Common side effects include nausea, breast tenderness, headache, and breakthrough bleeding, especially in the first few months.,Seek medical attention if you experience leg pain, chest pain, shortness of breath, severe headache, vision changes, or jaundice.,Do not smoke while taking this medication as it increases the risk of serious cardiovascular side effects.,Inform your healthcare provider of all medications you are taking, including over-the-counter drugs and supplements.,This medication does not protect against sexually transmitted infections; use condoms for STI prevention.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LO MINASTRIN FE vs LARIN 1.5/30, answered by our medical review team.
LO MINASTRIN FE is a Combination Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Inhibits ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, inhibiting sperm penetration; alters endometrial lining, reducing implantation likelihood.. LARIN 1.5/30 is a Combination Oral Contraceptive that works by Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LO MINASTRIN FE and LARIN 1.5/30 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LO MINASTRIN FE is: 1 tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol/ferrous fumarate 75 mg) orally once daily for 28 consecutive days.. The standard adult dose of LARIN 1.5/30 is: One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LO MINASTRIN FE and LARIN 1.5/30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LO MINASTRIN FE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester use associated with cardiovascular defects, neural tube defects; second/third trimeste. LARIN 1.5/30 is classified as Category C. First trimester: No consistent evidence of major malformations, but a small increased risk of cardiovascular defects and oral clefts cannot be excluded. Second and third trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.